Not just a better treatment — a totally novel approach
We aim to protect the healthy cells, expose the cancer.
We are working to bring the possibility of a cure to patients with high-risk AML, a disease that carries a poor prognosis even with aggressive therapies including traditional Hematopoietic Stem Cell Transplant (HSCT), which has been the standard of care for decades.
Vor Bio is developing a novel treatment approach—Edit HSCs to enable treatment with powerful targeted therapies post-transplant.
Vor Bio is developing a proprietary platform built on HSC biology, genome engineering, and CAR-T cells.
Our platform is driving multiple programs in our pipeline.
We are investing in our own manufacturing facilities and have designed a highly-efficient process for manufacturing our eHSCs and CAR-Ts.
Our vision of a cure for blood cancers is only possible with the collaborative efforts of first-class external partners.